Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens With the new pill, most participants experienced fewer lipid-related side effects, such as increased cholesterol levels, suggesting an additional potential benefit for those at risk of heart disease.

Living with #HIV (including among #LGBT #PLHIV): A new, daily oral tablet that combines two current HIV treatment medications, #bictegravir and #lenacapavir, may be able to replace more HIV treatment regimens for long-term survivors.
outragemag.com/single-daily...

Gilead data show investigational HIV combination maintains viral suppression - PharmaTimes New phase 3 results highlight potential alternative for adults switching from complex regimens

#virology #HIV #Gilead #Biktarvy #viralsuppression #ARTISTRY1 #ARTISTRY2 #ConferenceonRetrovirusesandOpportunisticInfections #bictegravir #lenacapavir #multitabletantiretroviralregimens #TheLancet #ARTISTRYdata #integrasestrandtransferinhibitor #capsidinhibitor
zurl.co/T0S4R

New Data on Bictegravir-Lenacapavir Combination for Sustained Viral Suppression in HIV Patients Recent clinical trials show that the new single-tablet regimen of BIC/LEN maintains viral suppression in HIV patients switching therapies, showcasing a significant advancement in treatment options.

New Data on Bictegravir-Lenacapavir Combination for Sustained Viral Suppression in HIV Patients #United_States #Foster_City #Gilead #Bictegravir #Lenacapavir

Colourful i-Base graphic. The main text reads: New once-daily HIV pill can reduce pill burden for many people on older complex ART. In the top left is i-Base’s website address: I hyphen base dot info. A smaller rectangle in the bottom right, reads: HIV news. 2026. CROI 2026, is in the top right corner with CROI’s logo, a colourful illustration of the HIV virus. At the bottom, text reads, Denver, Colorado. February 22nd to 25th. Large colourful virus illustrations are faintly seen in the background of the image. The colours used in the image are pale blue, pale green, orange, dark blue, purple, turquoise, yellow, white, pink, green and black.

Once-daily oral BIC/LEN in ARTISTRY studies simplifies #HIVtreatment for those on complex combinations:

i-base.info/htb/53317

Reducing the pill burden for people on several tablets a day due to #DrugResistance will improve quality of life.

#CROI2026 #HIV #HIVsky #Gilead #bictegravir #lenacapavir

Colourful i-Base graphic. The main text reads: INSTI-based ART. Risk factor for metabolic syndrome? At the top is i-Base’s website address: I hyphen base dot info. At the bottom it says, subscribe by email. A smaller, tilted square graphic on the right, reads: HTB news. 2025. HIV treatment, prevention, access, and more. The colours used in the image are two shades of light green, dark purple, magenta, teal, light blue, lilac, orange mustard, dark blue, red, and white.

Is starting ART with #bictegravir or #dolutegravir a risk factor for developing #MetabolicSyndrome?

The #MITCLAN trial published in AIDS journal shows it could be:

i-base.info/htb/51254

#HIVsky #ResearchSky #ARVs #IntegraseInhibitors #INSTIs

Bictegravir use during pregnancy

[Publication] The article "Bictegravir use during pregnancy" is now available.

www.sciencedirect.com/science/arti...

#IDsky #Pregnancy #Bictegravir

Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer's Disease - PubMed Alzheimer's disease is a neurodegenerative disease that continues to have a rising number of cases. While extensive research has been conducted in the last few decades, only a few drugs have been appr...

Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer’s Disease #C4b #Bictegravir #MECFS #LongCovid

pubmed.ncbi.nlm.nih.gov/39897171/